<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44979">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520752</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280A2103</org_study_id>
    <nct_id>NCT02520752</nct_id>
  </id_info>
  <brief_title>A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drg-drug Interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of
      midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2015</start_date>
  <completion_date type="Anticipated">July 5, 2017</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of midazolam and caffeine</measure>
    <time_frame>Up to 72 hours post midazolam and caffeine dose</time_frame>
    <description>midazolam and caffeine pharmacokinetic parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on the CTCAE v4.03 grade (severity) and other safety data (e.g.,ECG, vital signs, laboratory results)</measure>
    <time_frame>From consent to 30 days post last dose</time_frame>
    <description>To assess safety and tolerability of INC280 in patients with cMET-dysregulated advanced solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate of patients treated with INC280</measure>
    <time_frame>Baseline, every 6 weeks</time_frame>
    <description>Overall response rate is defined as Complete Response and Partial Response calculated per RECIST 1.1, per investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of patients treated with INC280</measure>
    <time_frame>Baseline, every 6 weeks</time_frame>
    <description>Disease control rate is defined as calculated as the proportion of patients with best overall response of Complete Response, Partial Response, or Stable Disease calculated per RECIST 1.1, per investigator assessment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>cMET-dysregulated Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must have:

          -  advanced solid tumors and have confirmed cMET dysregulation

          -  at least one measurable lesion as defined by RECIST 1.1.

          -  recovered from all toxicities related to prior anti-cancer therapies

          -  adequate organ function

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

        Patients must not have:

          -  known hypersensitivity to any of the excipients of INC280 or to benzodiazepines or
             known intolerance and hypersensitivity to caffeine

          -  symptomatic central nervous system (CNS) metastases who are neurologically unstable

          -  presence or history of carcinomatous meningitis

          -  history of another primary malignancy that is currently clinically significant or
             currently requires active intervention

          -  Clinically significant, uncontrolled heart diseases, including QTcF ≥ 450 ms (male
             patients), ≥ 460 ms (female patients) on the screening ECG

          -  Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280

          -  Major surgery within 4 weeks prior to starting INC280

          -  Patients receiving unstable or increasing doses of corticosteroids.

          -  Impairment of GI function or GI disease that may significantly alter the absorption
             of INC280

          -  Patients who have received or consumed, or are expected to receive or consume
             midazolam or caffeine-containing products (e.g., tea, coffee, cola), within 2 days
             prior to Day 1 and during the whole duration of the DDI phase (i.e., from Day -2 to
             Day 12)

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute SC-2</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/Siteman Cancer Center</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>August 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cMET, INC280, caffeine, midazolam</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
